Fluicell launches BioPen in new market through exclusive distribution agreement in Israel
Fluicell AB (publ), a single-cell instrumentation company within life science, today announced a new sole and exclusive distribution agreement with New Bio Technology Ltd. for the sale and distribution of Fluicell’s BioPen® System in Israel. The agreement is coming into effect on the 12th June 2018 and marks the company’s entry into a new geographical area. Fluicell’s products are available in selected markets across Europe, North and South America, Asia and Australia, increasing its global footprint and reach within single-cell biology research.
The sole and exclusive distributor agreement was signed today between Fluicell and New Bio Technology Ltd. (NBT), a leading distributor of reagents and equipment in fields such as neurobiology, psychology, physiology and pharmacology in Israel. The agreement comes into effect on the 12th June 2018 and will be available to NBT’s existing customers and exhibited at key conferences around Israel.
“This is a great milestone for us as we make our products available in yet another country, now Israel is one of those. It has always been of importance to increase our distribution network but only with the right partners that already have a solid market presence, which is why we are now delighted to work with NBT. We look forward to seeing our products being available for game-changing research in Israel,” said Victoire Viannay, CEO at Fluicell.
The BioPen® System is a solution delivery platform that enable researchers to perform localized drug delivery in very small doses to single-cells and tissues. It comprises the two products BioPen® PRIME and BioPen® FLEX, which are developed to suit the two most common types of microscope within laboratory research. Both products are tailored to enable cost-effective drug development and medical research, primarily targeting academia, research laboratories as well as pharmaceutical and biotech companies.
“We pride ourselves on offering tailored research solutions with the finest research equipment and have built a solid reputation among our customer in Israel. Our customer-base is in the hundreds and include universities, hospitals, research labs, private companies and research institutes. We look forward to entering into this agreement with Fluicell and its BioPen® System which, we believe, will bring real-change to single-cell research,” said Uri Schechter CEO at NBT.
Fluicell products are currently available in more than 15 countries around the world through a network of distributors. The company is looking at expanding its distribution in strategic markets and are continuously evaluating promising distribution partners that share Fluicell’s values and vision.